WT1 and acute myeloid leukemia: In an early phase II clinical trial, acute myeloid leukemia patients were vaccinated by intradermal injection with autologous DC electroporated in vitro with mRNA, encoding Wilms ́ tumor 1 (WT1) antigen in bi-weekly intervals for four cycles [62].